- Vertex Pharmaceuticals Incorporated stock price today and history
Vertex Pharmaceuticals Incorporated (VRTX) stock prices updated...
Please, Signup (Login) to subscribe or trade (demo)
Vertex Pharmaceuticals Incorporated stock price
Vertex Pharmaceuticals Incorporated latest news:
Vertex Pharma surges 1% after news of new CFO
Vertex Pharmaceuticals Inc. shares surged 1.2% in premarket trade Wednesday after the company announced that Tom Graney would be its new chief financial officer and senior vice president, starting September 13. Graney will report to Ian Smith, Vertex's chief operating officer and executive vice president, who has been Vertex's chief financial officer for 16 years. Graney most recently served as CFO and senior vice president of finance and corporate strategy at Ironwood Pharmaceuticals . Graney was in his Ironwood Pharma position for just over three years, according to his LinkedIn profile; he previously worked at Johnson & Johnson and its Ethicon and Janssen business units, among other places. Vertex shares have surged 24.6% to $159.07 over the last three months, compared with a 1.2% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Vertex Pharma reports quarterly profit
Vertex Pharmaceuticals Inc(VRTX) reported a quarterly profit, compared with a year-ago loss, helped by higher sales of its cystic fibrosis drugs. The company's net profit was $18 million, or 7 cents per share, in the second-quarter ended June 30, compared with a loss of $64.5 million, or 24 cents per share, a year earlier. Excluding items, the company earned 39 cents per share.
Morgan Stanley and Vertex jump while McCormick slides
Morgan Stanley, Vertex Pharmaceuticals and Scripps Networks Interactive climb while McCormick and IBM drop
Vertex Pharma shares rally on cystic fibrosis drug study results
Vertex Pharmaceuticals Inc. shares surged in the extended session Tuesday after the biotech drug maker announced positive results from clinical trials of its cystic fibrosis treatments. Vertex shares rallied 26% to $166.50 after hours. The company said data from clinical studies of its treatment candidates VX-152 and VX-440 showed an up to 12% average improvement in lung function in cystic fibrosis patients given the drugs. Cystic fibrosis is a genetic defect that causes an abnormal buildup of mucus in the lungs leading to chronic infection and progressive lung damage.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Vestin Realty Mortgage I, Inc.VRTA
Vestin Realty Mortgage II, Inc.VRTB
Viavi Solutions Inc.VIAV
Vident Core U.S. Bond Strategy FundVBND
Vident Core US Equity ETFVUSE